Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026

FATE vs VCYT: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

VCYT Wins Head-to-Head Institutional Verdict (5–1 across 6 Pillars · 8–2 Matrix Metrics)

VCYT Overall Winner 6-Pillar Tally: FATE 1 – 5 VCYT Matrix Metrics: FATE 2 – 8 VCYT

As of Nov 16, 2026, Veracyte, Inc. (VCYT) is the stronger overall head-to-head candidate over Fate Therapeutics, Inc. (FATE) in the Tradestie Institutional Equity Comparison Engine, winning 8–2 core matrix metrics and 5–1 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). FATE carries a Unified Composite Score of 43.0/100 (HOLD) at $1.14 (N/M Forward P/E, -2736.9% operating margin), whereas VCYT carries 49.1/100 (HOLD) at $24.01 (15.3x Forward P/E, 15.0% operating margin).

  • Technical & Structure Timing Caution: FATE is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 20.9); meanwhile VCYT is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 27.8). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About FATE vs VCYT
FATE NASDAQ
Fate Therapeutics, Inc.
Biological Products, (No Disgnostic Substances)
$1.14
-10.94% 1D
Market Cap $155.7M
TTM Revenue $4.8M
Forward P/E N/M
Beta / 30D Vol 2.16β · 104% Vol
Unified Composite Score
43.0 / 100 HOLD
Tech 25.0 Fund 47.0 Flow 67.0 Mom 55.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -10.8%), weak momentum, RSI 21
RSI-14: 20.9 · SMA20: $1.89 · SMA50: $2.13
VCYT NASDAQ Head-to-Head Winner
Veracyte, Inc.
Services-Medical Laboratories
$24.01
-1.32% 1D
Market Cap $2.0B
TTM Revenue $582M
Forward P/E 15.3x
Beta / 30D Vol 3.01β · 199% Vol
Unified Composite Score
49.1 / 100 HOLD
Tech 55.0 Fund 56.0 Flow 57.0 Mom 55.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -3.8%), weak momentum, RSI 28
RSI-14: 27.8 · SMA20: $39.20 · SMA50: $41.79

6-Pillar Scorecard Institutional Category Breakdown (FATE 1 – 5 VCYT)

Columns: Metric · FATE · VCYT
1. Valuation Multiples VCYT
Forward P/E N/M 15.3x
Trailing P/E N/M 15.8x
PEG Ratio N/M N/M
EV / Revenue 39.2x 3.1x
2. Growth & Scale VCYT
Revenue Growth (YoY) +9.2% +15.1%
Earnings Growth (YoY) +0.0% +58.3%
TTM Revenue (USD) $4.8M $582M
Market Cap $155.7M $2.0B
3. Profitability & Quality VCYT
Gross Margin N/A 74.2%
Operating Margin -2736.9% 15.0%
Net Profit Margin 0.0% 21.8%
Return on Equity (ROE) -67.8% 9.4%
4. Balance Sheet & Cash Flow VCYT
Cash Generation (TTM) -$107M $162M
Cash Flow Margin N/A 27.8%
Net Cash / Leverage $31M Net Debt (0.56x D/E) $159M Net Cash
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning FATE
Options Structure Phase BREAKDOWN BREAKDOWN
Current IV / %ile 169.0% (20th %ile) 197.3% (47th %ile)
Put/Call OI Skew 1.52x (Put-Skewed) 0.01x (Call-Skewed)
OBV Trend / Tech Phase DISTRIBUTION · Markdown DISTRIBUTION · Markdown
6. R&D & Supply-Chain Moat VCYT
OpEx & R&D Intensity N/A 59.2% of Rev ($344M)
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Scale & Operating Efficiency Moat
Supply-Chain Role Biotechnology Operator Diagnostics & Research Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: FATE (2) vs VCYT (8)
Institutional Metric FATE VCYT Criterion Row Edge
Market Capitalization
Scale
$155.7M $2.0B Larger Scale VCYT
Trailing P/E Ratio
Valuation
N/M 15.8x Lower Multiple VCYT
Forward P/E Ratio
Valuation
N/M 15.3x Lower Multiple VCYT
Revenue Growth (YoY)
Growth
+9.2% +15.1% Higher Growth VCYT
Operating Margin (TTM)
Profitability
-2736.9% 15.0% Higher Margin VCYT
Net Profit Margin
Profitability
0.0% 21.8% Higher Margin VCYT
Return on Equity (ROE)
Capital Efficiency
-67.8% 9.4% Higher ROE VCYT
52-Week Range Position
Momentum
8% ($1–$3) 5% ($22–$61) Stronger Trend FATE
Beta / 30D Volatility
Risk Regime
2.16β · 104% Vol 3.01β · 199% Vol Lower Realized Risk FATE
Unified Institutional Score
Composite Signal
43.0 / 100 (HOLD) 49.1 / 100 (HOLD) Higher Composite VCYT
Trailing 12M Revenue (USD)
Operating Scale
$4.8M $582M FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
N/A 74.2% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · 39.2x EV/Rev N/M PEG · 3.1x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$107M ($31M Net Debt (0.56x D/E)) $162M ($159M Net Cash) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon FATE +8.01 pp
FATE: -36.31% · VCYT: -44.32%
3M Horizon VCYT +14.49 pp
FATE: -55.47% · VCYT: -40.98%
6M Horizon FATE +8.04 pp
FATE: -34.1% · VCYT: -42.14%
1Y Horizon FATE +54.66 pp
FATE: +14.88% · VCYT: -39.78%

Financial Trajectory Multi-Year Annual Revenue & Operating Margin Trajectory (USD)

Split-Invariant USD Revenue & Operating Margin (%)
Period FATE Revenue VCYT Revenue FATE Op. Margin VCYT Op. Margin Margin Leader
FY2018 $0M $90M -1415.4% -24.2% VCYT
FY2019 $10M $120M -943.1% -12.6% VCYT
FY2020 $30M $120M -407.5% -30.1% VCYT
FY2021 $60M $220M -388.6% -37.3% VCYT
FY2022 $100M $300M -320.2% -13.9% VCYT
FY2023 $60M $360M -299.9% -23.8% VCYT
FY2024 $10M $450M -1542.6% 3.6% VCYT
FY2025 $10M $520M -2222.4% 11.2% VCYT

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
FATE BREAKDOWN
118d in phase · OBV DISTRIBUTION
Current IV 169.0%
IV Percentile 20th %ile
Put/Call OI Skew 1.52x (Put-Skewed)
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow DISTRIBUTION
Exact FATE Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
VCYT BREAKDOWN
99d in phase · OBV DISTRIBUTION
Current IV 197.3%
IV Percentile 47th %ile
Put/Call OI Skew 0.01x (Call-Skewed)
IV Regime Balanced (25th–60th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BEARISH
OBV Flow DISTRIBUTION
Exact VCYT Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
FATE Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $155.7M market capitalization and -2736.9% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
VCYT Moat Profile Scale & Operating Efficiency Moat
Diagnostics & Research Operator
Competes within the Diagnostics & Research value chain with $2.0B market capitalization and 15.0% operating margin.
OpEx & R&D Reinvestment 59.2% of Rev ($344M)
90D Engineering Disclosures 0 Published

Investor FAQ FATE vs VCYT Key Questions & Quantitative Answers

As of Nov 16, 2026, Veracyte, Inc. (VCYT) is the stronger overall head-to-head candidate over Fate Therapeutics, Inc. (FATE) in the Tradestie Institutional Equity Comparison Engine, winning 8–2 core matrix metrics and 5–1 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). FATE carries a Unified Composite Score of 43.0/100 (HOLD) at $1.14 (N/M Forward P/E, -2736.9% operating margin), whereas VCYT carries 49.1/100 (HOLD) at $24.01 (15.3x Forward P/E, 15.0% operating margin). Technical & Structure Timing Caution: FATE is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 20.9); meanwhile VCYT is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 27.8). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

VCYT leads the Growth & Scale pillar: FATE posts +9.2% YoY revenue growth and +0.0% YoY earnings growth on $4.8M TTM revenue (N/A gross margin, -2736.9% operating margin), compared with VCYT at +15.1% YoY revenue growth and +58.3% YoY earnings growth on $582M TTM revenue (74.2% gross margin, 15.0% operating margin). Across the 8-period historical trajectory (FY2018 to FY2025), FATE cumulative revenue shifted +0.0% while VCYT shifted +477.8%. In operating R&D and SG&A reinvestment, FATE deploys N/A (0 90-day corporate R&D disclosures) versus 59.2% of Rev ($344M) (0 disclosures) for VCYT.

VCYT screens cheaper on headline valuation multiples. FATE trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 39.2x EV/Revenue (unreported FCF margin), whereas VCYT trades at 15.3x Forward P/E, 15.8x Trailing P/E, N/M PEG, and 3.1x EV/Revenue (27.8% FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against FATE (-67.8% ROE) versus VCYT (9.4% ROE) capital efficiency.

In options market volatility and institutional positioning, FATE carries 169.0% implied volatility (20th %ile, Compressed (<25th %ile)), a 1.52x (Put-Skewed) Put/Call open-interest ratio, DISTRIBUTION on-balance volume, and sits in a BREAKDOWN options structure phase (2.16β · 104% Vol realized risk). By comparison, VCYT carries 197.3% implied volatility (47th %ile, Balanced (25th–60th %ile)), a 0.01x (Call-Skewed) Put/Call open-interest ratio, DISTRIBUTION on-balance volume, and sits in a BREAKDOWN options structure phase (3.01β · 199% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.